PARP inhibitors

October 7, 2019

Veliparib-Chemo Combo Prolongs Survival Without Disease Progression in Certain Advanced Breast Cancer Patients, Phase 3 Trial Shows

News

Veliparib in combination with chemotherapy significantly prolongs survival without disease progression in women with metastatic HER2-negative breast cancer with BRCA mutations, compared with women on chemotherapy alone, a Phase 3 ... Read more

March 27, 2017March 27, 2017

PARP Inhibitors Could Help More Breast Cancer Patients than Previously Thought, U.K. Study Suggests

News

PARP inhibitors like Lynparza (olaparib) were designed to treat patients with inherited BRCA1 or BRCA2 mutations, but more women with breast cancer could benefit from these drugs, a study suggests. ... Read more

February 2, 2016February 2, 2016

Breast Cancer Study Supports Effectiveness of New Class of Drugs Under Testing

News

Combining PARP inhibitors with inhibitors targeting an oncogene known as c-MET, which is overexpressed in many cancers, may enhance treatment results. These findings, published in the journal Nature Medicine, could prove important for future ... Read more

August 18, 2014August 18, 2014

Why Women Need To Know About PALB2 & Breast Cancer Risk

Breast Cancer News, News

A recent study has shown that women who are found to have mutations in the gene known as PALB2 are also likely to have a 1 in 3 chance of being diagnosed with breast cancer by ... Read more